Cognizant Technology Solutions news

CTSH demonstrates superior value characteristics with a lower forward P/E ratio (9.89), lower PEG ratio (1.06), and a strong Value grade of A. Combined with a Zacks Rank #2 (Buy) indicating positive earnings estimate revisions, it is positioned as the better value investment option.

Cognizant and its subsidiary TriZetto won the litigation with a substantial $236.9 million award, including compensatory damages, punitive damages, and attorneys' fees. This represents a favorable court decision and financial recovery.

As the parent company of TriZetto Provider Solutions, Cognizant faces reputational risk and potential financial liability from the subsidiary's data breach affecting millions of individuals.

Mentioned as a competitive threat to ExlService among global IT and data-services providers, but no specific performance data provided.

Listed as a key company providing services and implementation support for clinical data analytics solutions, benefiting from the services segment growing at 27.5% CAGR.

Mentioned only as a top holding (0.71% of assets) with no performance commentary or analysis provided.

Mentioned as the largest individual holding in FXL at 2.27% of total assets, but no performance or sentiment analysis provided.

Cognizant showed modest revenue growth of 4.5% YoY and slight EPS improvement from $1.31 to $1.37. The stock gained 13.7% over the past month but carries a Zacks Rank #3 (Hold) rating. Consensus estimates remained unchanged over the last 30 days, indicating stable but unexciting near-term prospects.

Cognizant is mentioned as an early adopter of Claude AI across its 350,000 employees, indicating investment in AI capabilities, but the article provides no information about financial impact or strategic significance to the company.

Identified as a key player in the growing pharmacovigilance automation market with service offerings.

Listed as a key player and specifically mentioned for strengthening cloud-based legal operations and AI-driven document review platforms in 2025, demonstrating active expansion in the growing market.

Fell 10.4% on Accenture's negative guidance read-across affecting the entire digital-consulting cohort

Removed from the Nasdaq-100 Index, indicating it no longer qualifies as one of the largest Nasdaq-listed non-financial companies

Identified as service provider supporting AI implementation in life sciences

Cognizant is mentioned only as the acquirer of Thirdera (the previous employer of Naitiv's founders). The article does not indicate any direct business relationship or impact on Cognizant from Naitiv's launch.

Listed as a major player in the growing pharmacovigilance market, benefiting from increased demand for outsourced drug safety and compliance services.